汇宇制药：两产品获荷兰、沙特上市许可

Core Viewpoint - Sichuan Huiyu Pharmaceutical Co., Ltd. announced that its subsidiary has received marketing approvals for injectable Parecoxib Sodium and injectable Pemetrexed Disodium from the drug regulatory authorities in the Netherlands and Saudi Arabia respectively [1] Group 1: Product Approvals - Injectable Parecoxib Sodium is indicated for short-term pain management in adults post-surgery and has already been approved in the UK and the Netherlands, with an application submitted in Germany [1] - Injectable Pemetrexed Disodium is used for the treatment of related cancers and has been approved in 14 countries, with applications submitted in 10 additional countries and regions [1] Group 2: Strategic Implications - The recent approvals are expected to enrich the international pipeline and enhance the brand image of the company [1] - However, future sales remain uncertain, and the short-term impact on performance is not expected to be significant [1]